Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012 Mar;3(2):106-11.

Understanding waterfall plots

Theresa W Gillespie  1
Affiliations
Review

Understanding waterfall plots

Theresa W Gillespie. J Adv Pract Oncol. 2012 Mar.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Figure 1. Best response for target lesions by patient, based on maximal percentage of tumor reduction. RECIST = Response Evaluation Criteria in Solid Tumors. Reprinted, with permission, from Socinski et al. (2008).
Figure 2
Figure 2
Figure 2. Response to ALK inhibition: percent change in tumor burden. Adapted, with permission, from Kwak et al. (2010).
Figure 3
Figure 3
Figure 3. Best response to crizotinib in 31 patients with ALK-positive tumors, as correlated with clinicopathologic characteristics. Adapted, with permission, from Kwak et al. (2010).
Figure 4
Figure 4
Figure 4. (A) Duration of treatment and (B) estimated progression-free survival (gold curves represent 95% Hall-Wellner confidence limits). Adapted, with permission, from Kwak et al. (2010).
See this image and copyright information in PMC

References

    1. Allison P. Survival analysis using the SAS system: A practical guide. Cary, NC: SAS Institute. 1995
    1. Campbell M. E., Grothey A., Sargent D. J., Goldberg R. M. Waterfall plots provide detailed information on magnitude of response to conventional chemotherapy in advanced colorectal cancer (ACRC)—Lessons learned from N9741 [Abstract 4080]. Journal of Clinical Oncology. 2007;25(suppl June 20)
    1. Kwak E. L., Bang Y.-J. , Camidge R., Shaw A. T., Solomon B., Maki R. G., afrate A. J. Anaplastic lymphoma kinase inhibition in non-small cell lung cancer. New England Journal of Medicine. 2010;363:1693–1703. - PMC - PubMed
    1. Socinski M. A., Novello S., Brahmer J. R., Rosell R., Sanchez J. M., Belani C. P., Scagliotti G. V. Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. Journal of Clinical Oncology. 2008;26:650–656. - PMC - PubMed
    1. Wahl R. L., Jacene H., Kasamon Y., Lodge M. A. From RECIST to PERCIST: Evolving considerations for PED response criteria in solid tumors. Journal of Nuclear Medicine. 2009;50:122S–150S. - PMC - PubMed

LinkOut - more resources